MDIC's Early Feasibility Studies project team collaborated to develop this resource with input from regulators, medical device manufacturers, and clinicians. In 2025, MDIC partnered with Veranex to implement the development of the EFS Explorer.

MDIC and Veranex acknowledge the Heart Valve Collaboratory (HVC) for their early engagement and contributions to advancing Early Feasibility Studies (EFS), which helped inform the development of the EFS Explorer project. Their prior work in this space provided valuable context and insights that supported the program's evolution.

The EFS Explorer was developed by the Medical Device Innovation Consortium (MDIC) in collaboration with Veranex Inc. , and leading clinical sites as part of MDIC's mission to accelerate early feasibility studies and strengthen U.S. innovation infrastructure.

The EFS Explorer, built on information from ClinicalTrials.gov, centralizes key data and resources related to Early Feasibility Studies. This tool makes it easier for EFS sponsors, sites, and other stakeholders to identify and engage with qualified clinical sites with prior EFS experience.

By drawing on publicly available trial information and combining it with MDIC's curated EFS tools, EFS Explorer reduces fragmented outreach and redundant data collection. Finally, you'll be able to employ a single, standardized platform with up-to-date site information, best-practice templates (EFS playbook, contracting), and insights that help accelerate first-in-human device trials in the U.S.

• Medical-device sponsors looking for EFS-ready sites and streamlined start-up processes.
• Clinical research sites interested in showcasing their EFS capabilities and connecting with sponsors.
• Regulators, payers, and academic partners who want visibility into the national EFS ecosystem and tools that support faster, safer innovation.

In short, anyone involved in planning, conducting, or supporting early-stage device trials can benefit.

We plan to expand functionality to let clinical sites self-report on key site-selection criteria that sponsors routinely request, confirm use of the EFS Clinical Trial Agreement (CTA) and EFS Site Qualification Questionnaire, and integrate other MDIC EFS resources (toolkits, templates, metrics dashboards). These future planned enhancements will streamline sponsor-site matching, increase transparency across the EFS ecosystem and, as a result, reduce study start-up delays.